Research and Markets: Roche's Kadcyla (HER2-Positive Breast Cancer) Forecast and Market Analysis to 2023

Research and Markets (http://www.researchandmarkets.com/research/pwn7zw/kadcyla) has announced the addition of the "Kadcyla (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023" report to their offering.

Kadcyla (ado-trastuzumab) is Roche's third HER2-targeted mAb, approved by the FDA in February 2013, by the Japanese MHLW in September 2013, and by the EMA in November 2013, for the second-line treatment of metastatic HER2-positive breast cancer. Kadcyla is an antibody-drug conjugate consisting of trastuzumab covalently linked to the microtubule inhibitor, DM1 (mertansine) via a non-reducible thioether linkage (MCC).

Scope

• Overview of HER2-Positive Breast Cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on Kadcyla including product description, safety and efficacy profiles as well as a SWOT analysis.
• Sales forecast for Kadcyla for the top eight countries from 2013 to 2023.
• Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and China.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

• Etiology and Pathophysiology
• Basic Breast Anatomy
• Breast Cancer Staging
• Prognosis
• Quality of Life
• Symptoms

4 Disease Management

• Treatment of Early-Stage Breast Cancer (Stage 0 to Stage IB)
• Treatment of Locally-Advanced and Regional Breast Cancer (Stage IB to IIIA)
• Treatment of Metastatic HER2-Positive Breast Cancer (Stage IV)

5 Competitive Assessment

6 Kadcyla (ado-trastuzumab emtansine, T-DM1)

• Overview
• Efficacy
• Safety
• SWOT Analysis
• Forecast

7 Appendix

For more information visit http://www.researchandmarkets.com/research/pwn7zw/kadcyla